Hair loss is not the side effect most people expect from a weight-loss drug — but it is making headlines this week. Kimberly-Clark’s chief executive said Rogaine sales are up about 30 percent this year, and that the rise may be driven in part by GLP-1 use, according to the Financial Times. Novo Nordisk and Eli Lilly are publicly defending their drugs amid wider side-effect scrutiny. What does the evidence say — and why does it matter legally?
What the Labels Say — and Don’t Say
Start with the labels, because they do not match. Wegovy, the weight-loss brand of semaglutide, lists alopecia — hair loss — on its FDA label, reported by 3 percent of users in the STEP 1 trial, compared with 1 percent of people on placebo. Ozempic, the diabetes brand of the same active ingredient, semaglutide, does not list hair loss as a common side effect. Ozempic is given at a lower diabetes dose, and it is also widely used off-label for weight loss. Same drug, two labels, two different warnings.
The research points the same way. A 2025 University of British Columbia study found that people using semaglutide for weight loss were about 52 percent more likely to report hair loss than people using a different weight-loss drug, bupropion-naltrexone. For women, the risk was about double.
Why It Happens — and Why Reversibility Depends on the Cause
In most cases, the mechanism is not the drug destroying hair follicles. It is telogen effluvium — diffuse shedding triggered by rapid weight loss and nutrient gaps, which push more hairs than usual into the resting, shedding phase. That kind of shedding is typically temporary: it peaks a few months after the rapid loss, and regrowth usually follows within 6 to 12 months once weight stabilizes.
The exception matters. In some people, the shedding unmasks or accelerates underlying pattern baldness — androgenetic alopecia — which does not fully reverse. That is why two people on the same drug can have opposite outcomes: reversibility depends on the cause, not just on the medication.
The Legal Frame — Carefully Stated
The existing GLP-1 lawsuits are about other injuries. A federal multidistrict litigation (MDL) covers gastrointestinal injuries such as gastroparesis and ileus, involving thousands of cases. A separate MDL covers NAION vision loss. Hair loss is not a claim category in either group, and there is no hair-loss verdict or settlement. The core theory there is failure to warn — which is why a side effect on Wegovy’s label but not Ozempic’s is legally interesting if claims ever develop. Interesting is not proven, and no such claim exists today.
What to Do If Shedding Starts
First, never stop a prescribed drug on your own — talk to your doctor. Second, if shedding starts, write down the dates, any dose changes, and how fast you are losing weight, and keep those records, along with photos and any medical notes. If a future claim ever turned on this issue, documentation is what it would turn on. Keep the records now, while they are easy to make.
Tacher Law
16445 Collins Avenue, Suite 1625
Sunny Isles Beach, FL 33160
Phone: +1 (305) 644-2211
Questions about a drug injury or another injury matter? Contact Tacher Law for a free consultation.
Disclaimer: This post is general information, not legal advice about any specific situation, and not medical advice. Talk to your doctor about any side effect or medication change. Reading this post does not create an attorney-client relationship.



Leave A Comment